Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Adams

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
Novel IKK inhibitors: beta-carbolinesAlfredo C Castro, Luan C Dang, François Soucy, et al.
Current Biology : CB|June 25, 2024
A multifaceted kinase axis regulates plant organ abscission through conserved signaling mechanismsSergio Galindo-Trigo, Virendrasinh Khandare, Mark Roosjen, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Protein Science : a Publication of the Protein Society|December 24, 2003
Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory siteJulian Adams, Zhi-Ping Chen, Bryce J W Van Denderen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profilingLloyd T Lam, R Eric Davis, Jackie Pierce, et al.
Molecular Cancer Therapeutics|January 9, 2003
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenograftsSteffan T Nawrocki, Christiane J Bruns, Matthew T Harbison, et al.
The Journal of Biological Chemistry|March 2, 2002
NF-kappa B as a therapeutic target in multiple myelomaTeru Hideshima, Dharminder Chauhan, Paul Richardson, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 9, 2002
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injuryJoseph Pye, Farhad Ardeshirpour, Arlene McCain, et al.
Molecular Oncology|August 10, 2019
Targeting CDK9 for treatment of colorectal cancerMuhammed H Rahaman, Frankie Lam, Longjin Zhong, et al.
Leukemia & Lymphoma|August 20, 2011
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myelomaDavid Siegel, Sundar Jagannath, David H Vesole, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
Novel IKK inhibitors: beta-carbolinesAlfredo C Castro, Luan C Dang, François Soucy, et al.
Current Biology : CB|June 25, 2024
A multifaceted kinase axis regulates plant organ abscission through conserved signaling mechanismsSergio Galindo-Trigo, Virendrasinh Khandare, Mark Roosjen, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Protein Science : a Publication of the Protein Society|December 24, 2003
Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory siteJulian Adams, Zhi-Ping Chen, Bryce J W Van Denderen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profilingLloyd T Lam, R Eric Davis, Jackie Pierce, et al.
Molecular Cancer Therapeutics|January 9, 2003
Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenograftsSteffan T Nawrocki, Christiane J Bruns, Matthew T Harbison, et al.
The Journal of Biological Chemistry|March 2, 2002
NF-kappa B as a therapeutic target in multiple myelomaTeru Hideshima, Dharminder Chauhan, Paul Richardson, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 9, 2002
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injuryJoseph Pye, Farhad Ardeshirpour, Arlene McCain, et al.
Molecular Oncology|August 10, 2019
Targeting CDK9 for treatment of colorectal cancerMuhammed H Rahaman, Frankie Lam, Longjin Zhong, et al.
Leukemia & Lymphoma|August 20, 2011
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myelomaDavid Siegel, Sundar Jagannath, David H Vesole, et al.
Pageof 7